Cargando…
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery
Chagas’ disease is responsible for significant mortality and morbidity in Latin America. Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed. However, recent efforts have proved unsuccessful with failure of the ergostero...
Autores principales: | MacLean, Lorna M., Thomas, John, Lewis, Michael D., Cotillo, Ignacio, Gray, David W., De Rycker, Manu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057682/ https://www.ncbi.nlm.nih.gov/pubmed/30001347 http://dx.doi.org/10.1371/journal.pntd.0006612 |
Ejemplares similares
-
Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
por: De Rycker, Manu, et al.
Publicado: (2016) -
Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box
por: Cantizani, Juan, et al.
Publicado: (2021) -
Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay
por: Svensen, Nina, et al.
Publicado: (2021) -
Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line
por: Alonso-Padilla, Julio, et al.
Publicado: (2015) -
The Q(i) Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani
por: Wall, Richard J., et al.
Publicado: (2020)